Eltrombopag olamine is an essential thrombopoietin receptor agonist. It effectively manages thrombocytopenia in patients with chronic immune thrombocytopenic purpura, hepatitis C, and aplastic anemia. A recent clinical trial investigated eltrombopag olamine bioequivalence to determine if a new generic formulation matches the reference drug. Ensuring therapeutic interchangeability is crucial for expanding treatment access and reducing healthcare costs in diverse populations.

Study Design and Methodology

Researchers conducted a single-center, randomized, open-label crossover study involving 36 healthy subjects. The trial compared a test formulation of 25 mg eltrombopag olamine against the reference product. Importantly, the participants received the medication after a low-calcium, high-fat, and high-calorie breakfast. This specific dietary condition is vital because calcium significantly impairs the absorption of this drug. Furthermore, the team utilized a 14-day washout period between the two treatment sequences to ensure accurate pharmacokinetic measurements.

Achieving Eltrombopag Olamine Bioequivalence

The study results demonstrated that the test formulation met all primary pharmacokinetic endpoints. Specifically, the geometric mean ratio for the maximum plasma concentration (Cmax) reached 92.68%. Moreover, the area under the curve (AUC) from time zero to the last measurable concentration was 97.15%. All 90% confidence intervals for these parameters fell strictly within the regulatory range of 80.00% to 125.00%. Therefore, the two formulations are considered pharmacokinetically equivalent under these dietary conditions.

Safety and Tolerability Profile

Safety monitoring occurred throughout the entire trial duration. Only nine subjects reported adverse events, totaling 14 occurrences. Notably, all reported events were mild (Grade 1), and no serious adverse events took place. This favorable safety profile confirms that the generic formulation is as well-tolerated as the reference drug. Consequently, these findings support the clinical use of the test tablet as a reliable alternative for treating low platelet counts.

Significance of Eltrombopag Olamine Bioequivalence in Clinical Practice

For clinicians, these results provide confidence in switching patients to cost-effective generic alternatives. Since the study confirmed bioequivalence in the fed state with low calcium, it highlights the importance of dietary management during therapy. Patients must still avoid calcium-rich foods like dairy for several hours around their dose to ensure optimal efficacy. Ultimately, this trial reinforces the therapeutic interchangeability of eltrombopag formulations, benefiting patients who require long-term hematological support.

Frequently Asked Questions

How does food affect the absorption of eltrombopag?

Food high in polyvalent cations, particularly calcium, can significantly reduce the absorption of eltrombopag. Therefore, patients should take the medication on an empty stomach or with a meal containing very low calcium (less than 50 mg). This study confirms that a low-calcium meal does not prevent the generic from reaching therapeutic levels equivalent to the brand name.

Are generic eltrombopag tablets as safe as the brand-name version?

Yes, bioequivalence studies require the test product to show a similar safety profile to the reference drug. In this trial, only mild Grade 1 adverse events occurred, with no serious safety concerns. This suggests the generic formulation is safe for clinical use.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or diagnosis. Refer to the latest local and national guidelines for clinical practice.

References

1. Wu K et al. A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State. Clin Drug Investig. 2026 Feb 07. doi: 10.1007/s40261-026-01528-0. PMID: 41653397.


2. U.S. Food and Drug Administration. Promacta (eltrombopag) Prescribing Information. Accessdata.fda.gov.


3. Mayo Clinic. Eltrombopag (Oral Route): Side Effects and Dosage. Mayoclinic.org.